Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Once upon a time, back in the 1960s, corporations and investors got excited about a new form of organization: the conglomerate. It seemed like a good idea at the time because cyclical companies could buy counter-cyclical companies and smooth out their earnings—in theory, at least.

Johnson & Johnson Pushes Ahead With Spinoff

Johnson & Johnson (NYSE: JNJ) released their financial report for the second quarter of 2022, this week, demonstrating strong growth and promising guidance for the rest of the year. Analysts seem to agree, as the consensus rating for JNJ is MODERATE BUY.

Things Looking Up at Johnson & Johnson?

Microsoft

These giant companies face the same headwind.

This Chart Shows a Big Problem for Johnson & Johnson, IBM, and Microsoft

Johnson & Johnson (NYSE: JNJ) reported a 3% growth in net sales to $24.02 billion, surpassing the consensus estimate of $23.81 billion, and a 4.4% growth in adjusted earnings to $2.59 per share, beating Street expectations of $2.57 per share. Raymond James On Johnson & Johnson: Analyst.

4 Analysts Takeaways From Johnson & Johnson's Quarterly Results: What Investors Need To Know

Stryker

Intuitive Surgical

Zimmer Biomet Hlds

While Johnson & Johnson's ( JNJ , Financial) Medtech sales were lower in the second quarter, revenue from hips and knee replacements was on target or above, a development that could spill over into segment competitors Stryker Corp. ( SYK , Financial) and Zimmer Bioment Holdings Inc. ( ZBH , Financial), as well as robotic surgery leader Intuitive Surgical Inc. ( ISRG , Financial), analysts said in a Fierce Pharma article.

J&J Medtech Outlook Boosts Shares of Stryker, Biomet and Intuitive

JPMorgan Chase & Co said on Tuesday Alex Gorsky, former chief executive officer of Johnson & Johnson, has been elected as a director of the bank.

JPMorgan adds former J&J chief Gorsky to board

Health care bellwether Johnson & Johnson topped second-quarter expectations Tuesday, but JNJ stock fell on its trimmed 2022 outlook. The post Here's The Surprising Driver Of J&J's Second-Quarter Beat, And Why It Didn't Help appeared first on Investor's Business Daily.

Here's The Surprising Driver Of J&J's Second-Quarter Beat, And Why It Didn't Help

Is Johnson & Johnson stock a sell after cutting its 2022 outlook amid currency concerns? Is JNJ stock a sell right now?

Medical Giant J&J Crumbles On Guidance Haircut — Is It A Sell Now?

Johnson & Johnson (NYSE:JNJ ) Q2 2022 Earnings Conference Call July 19, 2022 8:30 AM ET Company Participants Jessica Moore - Vice President, Investor Relations Joaquin Duato - Chief Executive Officer Joe Wolk - Chief Financial Officer Conference Call Participants Terence Flynn - Morgan Stanley Larry Biegelsen - Wells Fargo Chris Schott - JPMorgan Joanne Wuensch - Citi Louise Chen - Cantor Fitzgerald Josh Jennings - Cowen Chris Shibutani - Goldman Sachs David Risinger - SVB Securities Operator Good morning and welcome to Johnson & Johnson's Second Quarter 2022 Earnings Conference Call. [Operator Instructions] I would now like to turn the conference call over to Johnson & Johnson.

Johnson & Johnson (JNJ) CEO Joaquin Duato on Q2 2022 Results - Earnings Call Transcript

J&J (JNJ) beats estimates for second-quarter earnings as well as sales. It cuts the full-year outlook due to currency headwinds.

J&J (JNJ) Beats on Q2 Earnings & Sales, Lowers 2022 Guidance

Johnson & Johnson  (NYSE:JNJ ) took over the earnings confessional earlier to report a second-quarter earnings and revenue beat, thanks in part to the double-digit sales growth of cancer drug Darzalex and Crohn's disease drug Stelara.

Options Bulls Brush Off Johnson & Johnson's Lowered Outlook

Johnson & Johnson (NYSE: JNJ) shares are trading slightly higher Tuesday after the company announced better-than-expected financial results. Johnson & Johnson said second-quarter revenue increased 3% year-over-year to $24.02 billion, which beat the estimate of $23.81 billion, according.

Johnson & Johnson Stock Is Moving: What's Going On?

Johnson & Johnson (NYSE: JNJ) on Tuesday, July 19, posted quarterly earnings results, beating estimates across the board. However, not.

Johnson & Johnson beats earnings – JNJ stock rises in premarket trading

Shares of Johnson & Johnson JNJ, -2.24% gained 0.7% in premarket trading Tuesday, after the pharmaceutical and consumer health products company reported second-quarter profit and sales that beat expectations, offsetting a reduced full-year earnings outlook. Net earnings fell to $4.81 billion, or $1.80 a share, from $6.28 billion, or $2.35 a share, in the year-ago period.

Johnson & Johnson stock gains after profit and sales beat expectations, while full-year outlook was cut

(Reuters) -Johnson & Johnson on Tuesday cut its full-year adjusted profit forecast for the second straight quarter as a stronger dollar dragged on its sales outside the United States.

Johnson & Johnson profit outlook takes a knock from stronger dollar

Johnson & Johnson, the healthcare giant, trims its fiscal-year adjusted earnings outlook.

Johnson & Johnson Tops Profit Estimates but Trims Full-Year Outlook

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2022. “Our solid second quarter results across Johnson & Johnson reflect the strength and resilience of our Company's market leadership in the midst of macroeconomic challenges,” said Joaquin Duato, Chief Executive Officer. “I am continually energized by the focus and passion of my Johnson & Johnson colleagues and their dedication toward delivering transformative healthcare

Johnson & Johnson Reports Q2 2022 Results

Apple

Chevron

Home Depot

Altria

Procter & Gamble

Walmart

Exxon Mobil

Take care in buying dividend stocks, which like General Electric can collapse when they make mistakes, just like other stocks. The post 10 Best Dividend Stocks of All Time appeared first on InvestorPlace.

10 Best Dividend Stocks of All Time

AbbVie

Abbott Labs

Recession or no recession, these well-established businesses are going to keep on growing.

3 Dividend Growth Stocks You Can Buy Now and Hold Forever

JNJ Management expects relatively consistent growth for the rest of the year.

Johnson & Johnson Has Been Posting Negative Surprises: A Look Under The Hood

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that Michael (Mike) Ullmann will retire from his position as Executive Vice President, General Counsel at the end of this year, following 33 years of leadership and service to the Company. Throughout his distinguished career, Mr. Ullmann has worked with the organization's Board of Directors and partnered with four company CEOs to shape and grow Johnson & Johnson into the most broadly based healthcare com

Johnson & Johnson's Executive Vice President, General Counsel Michael Ullmann to Retire; Elizabeth Forminard Named General Counsel, Effective October 17, 2022

Johnson & Johnson is scheduled to release its second quarter earnings report on July 19, 2022. Low single-digit growth may not do much to excite investors.

Johnson & Johnson Continues to Prove its Value in a Volatile Year

3 Dividend Growth Stocks to Buy in July

Pfizer

UnitedHealth Group

Health and wealth; it doesn't get much better than that.

Want to Get Richer? 5 Best Stocks to Buy Now and Hold Forever

Johnson & Johnson will report its earnings results next week. A small profit increase is expected, as several macro factors diminish its near-term growth potential.

News for Johnson & Johnson Stock (JNJ)